Latest United States News

Vitrafy has added US blood network Versiti to its cryopreservation development programme, with the partnership focused on no-wash platelet preservation and regulatory verification. The deal strengthens the company’s institutional network, but initially generates no revenue and remains subject to US regulatory requirements.

Gowing Bros’ FY2026 loss widened to $3.49 million as Surf Hardware International remained deeply loss-making and investment properties were marked down by $3.0 million. The ASX-listed investment company kept its fully franked final dividend at 3 cents per share, despite negative operating cash flow and lower cash reserves.

Felix Gold advanced bulk extraction, processing and refinery plans at its Alaska antimony project in FY26, but the push came with a larger loss, falling cash and an auditor-documented material uncertainty over going concern. A potential US$18 million Department of Energy award remains subject to negotiation rather than a committed funding source.

AnteoTech has set sales conversion as its FY2027 priority after FY2026 sales revenue slipped to A$460,397, while operating expenses fell sharply and cash stood at A$11.2 million. The battery materials and life sciences company says customer evaluations and partnership discussions are building, but most opportunities remain short of recurring commercial revenue.

KTEK Aerosystems has restarted deliveries under its principal production program, with an initial batch ready for collection from its European manufacturing network. The company has also lifted stated monthly manufacturing capacity to 200 units, although future revenue remains dependent on output, acceptance and logistics.

Andromeda Metals completed key early works at its Great White kaolin project and achieved 99.9986% HPA purity at pilot scale. But a $98.9 million impairment, $3.2 million cash balance and material going-concern uncertainty leave funding as the decisive hurdle.

Red Mountain Mining’s annual report shows a sharp rise in losses and continued reliance on equity funding, with auditors flagging material uncertainty over the company’s ability to continue as a going concern. Exploration has expanded across antimony, tungsten and gold projects, but the portfolio remains dependent on future funding and successful drilling.

Cettire returned to positive operating cash flow in FY26, but its annual report carries a material uncertainty over going concern after current liabilities exceeded current assets by A$51.8 million. The luxury e-commerce group also posted an A$8.5 million statutory loss and is relying on working-capital discipline, VAT recoveries and potentially conditional director support.

Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.

Neuren says its partner Acadia has received a US Notice of Allowance for a trofinetide patent that could protect weight-banded dosing through 28 March 2041. The patent has not yet formally issued, but the allowance could extend US protection by almost five years beyond the existing method-of-use patent.

TradeWindow is targeting 13% to 18% revenue growth in FY27 and expects to approach EBITDA breakeven, while preparing to shift its primary listing from the NZX to the ASX. The freight software company also reported rising recurring revenue, stronger customer economics and NZ$4.0 million in cash at 30 June 2026.

Li-S Energy has narrowed its FY26 loss and reached several commercialisation milestones, including a 2C Power Cell, international shipping approvals and its first lithium foil sale. But the ASX battery developer still needs customer offtake and fresh funding before its proposed 1 GWh manufacturing expansion can become reality.